Table 6.
Summary of AEs related to pembrolizumab for Cohorts A, B, and C – All-treated population
| Cohort A | Cohort B | Cohort C | ||
|---|---|---|---|---|
| AEs | Pazopanib (800 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) n (%) |
Pazopanib (600 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) n (%) |
Pazopanib + pembrolizumab (N=6) n (%) |
Pembrolizumab (N=4) n (%) |
| Any event | 10 (100) | 10 (100) | 0 | 0 |
| Aspartate aminotransferase increased Alanine aminotransferase increased |
7 (70) 6 (60) |
6 (60) 5 (50) |
0 0 |
0 0 |
| Lipase increased Diarrhea |
0 5 (50) |
0 3 (30) |
2 (33) 2 (33) |
1 (25) 2 (50) |
| Arthralgia Pneumonitis |
0 0 |
0 0 |
0 2 (33) |
2 (50) 0 |
AE, adverse event; Q3W, every 3 weeks; QD, once daily.